IN BRIEF: MaxCyte Signs APN401 Licensing Deal With Apeiron Biologics

Wed, 08th Jul 2020 15:51

MaxCyte Inc - cell and gene therapies - Signs clinical and commercial licensing agreement with Apeiron Biologics AG. Apeiron to obtain non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation technology and ExPert platform for advancing APN401, a cell-therapy in development for solid tumours. MaxCyte will receive undisclosed development and approval milestones, with sales-based payments and licensing fees.

Current stock price: 208.80 pence

Year-to-date change: up 69%

By Dayo Laniyan; dayolaniyan@alliancenews.com

Related Shares

More News

11 Jun 2024 11:10

IN BRIEF: MaxCyte CEO Maher Masoud buys 100,000 shares

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies - Says Chief Executive Officer Maher Masoud acquired 100,00...

4 Jun 2024 14:27

UK shareholder meetings calendar - next 7 days

22 May 2024 21:51

IN BRIEF: MaxCyte inks deal with Legend Biotech for tech supply

MaxCyte Inc - Rockville, Maryland-based provider of cell engineering platform technologies developing "next-generation cell therapeutics" - Inks strat...

8 May 2024 12:45

MaxCyte reports strong first quarter

(Sharecast News) - MaxCyte reported total first-quarter revenue of $11.3m in an update on Wednesday, making for a 32% increase compared to the same pe...

8 May 2024 09:46

MaxCyte shares rise amid double-digit revenue increase

(Alliance News) - MaxCyte Inc on Wednesday reported a jump in its first quarter revenue, which it said was driven by its core business sales.